Allegro Diagnostics to Present Analytical Validation of BronchoGen at ATS International Conference

Maynard, Mass., May 17, 2013—Allegro Diagnostics today announced its participation in the American Thoracic Society International Conference, being held May 17-22, 2013 in Philadelphia. Duncan Whitney, Ph.D., Senior Vice President, Research, Development and Technical Operations, is presenting Poster #K43, entitled “Analytical Validation of BronchoGen™, An RT-PCR Gene-Expression Test To Improve The Diagnosis of Bronchoscopy For Lung Cancer” during the Molecular Mechanisms of Carcinogenesis Poster Session on Tuesday, May 21 from 8:15 a.m. to 4:30 p.m. in Area K (Halls C-D, 200 Level) of the Pennsylvania Convention Center. During the viewing, Dr. Whitney will present results of recent studies to develop and optimize prediction accuracy in a gene expression test for lung cancer.

Dr. Whitney and Avrum Spira, M.D., Professor of Medicine and Chief of the Division of Computation Biomedicine at Boston University School of Medicine, as well as a co-founder of Allegro Diagnostics, will also be available to answer questions about the clinical trials and development of BronchoGen in the Allegro Diagnostics booth (#1442) on Tuesday, May 21.

Also, on May 18, 2013, Michael D. Webb, President and CEO of Allegro Diagnostics, will present “Commercializing a Novel Molecular Diagnostic Test in Pulmonology” at the 2013 Spring Scientific Symposium of the American Association for Bronchology and Interventional Pulmonology, being held at the Hospital of University of Pennsylvania in Philadelphia.

About the Allegro Platform 

Allegro Diagnostics’ molecular testing platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer and diseases of the airway. The “field of injury” principle on which the platform is based refers to the detectable molecular changes that occur throughout the respiratory tract in response to smoking and are correlated with disease. These changes can be detected in a gene expression signature from cytologically normal airway cells and indicate the presence of malignancy or disease processes remotely in the lung. Allegro has applied this platform in multiple research programs for the detection of airway disease including COPD and lung cancer. Lung cancer tests based on sampling from the bronchus (BronchoGen™) and from the nasal passage (NasoGen™) have resulted from Allegro Diagnostics’ platform and are currently under development.
About Allegro Diagnostics
Allegro Diagnostics is a molecular diagnostics company focused on the development and commercialization of innovative genomic tests for the diagnosis, staging and informed treatment of lung cancer and other lung diseases. Allegro has developed a molecular testing platform that utilizes a genomic biomarker to detect early signs of lung cancer in current and former smokers. The company’s lead product is the BronchoGen™ genomic test for use in combination with standard bronchoscopy for the diagnosis of lung cancer.
Charles Liles
MacDougall Biomedical Communications
(781) 235-3060

Contact Info

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184